Novel Antimicrobial peptides effective against avian pathogenic Escherichia coli (APEC) and Salmonella

The Need: Microbial infections, particularly those caused by antibiotic-resistant pathogens like APEC and Salmonella, pose a significant commercial and health challenge. The demand for effective and innovative bioactive peptides capable of inhibiting these pathogens is escalating. Biotechnology companies and researchers are seeking novel approaches to combat infections and improve microbial therapeutics. To meet this need, we present a cutting-edge technology capable of identifying bioactive peptides in cell-free supernatants of probiotic strains, Lactobacillus rhamnosus GG (LGG) and Bifidobacterium lactis Bb12.

The Technology: Our proprietary technology employs state-of-the-art LC-MS/MS analysis, utilizing HyperSepTM HypercarbTM SPE cartridge, to identify bioactive peptides secreted by LGG and Bb12. These peptides demonstrate inhibitory potential against antibiotic-resistant pathogens, making them promising candidates for therapeutic development.

Commercial Applications:

  • Novel Therapeutic Agents: The identified bioactive peptides can serve as the basis for developing next-generation antimicrobial therapeutics, targeting infections caused by APEC and Salmonella.
  • Probiotic Enhancement: The technology can be leveraged to enhance the antimicrobial properties of probiotics, increasing their effectiveness in combating infections.
  • Agricultural Solutions: The bioactive peptides may have applications in animal health, offering a natural and sustainable alternative to antibiotics in livestock farming.


  • Targeted Antimicrobial Activity: The bioactive peptides have demonstrated significant inhibitory effects against APEC and Salmonella, specifically targeting antibiotic-resistant strains.
  • Bactericidal Action: The identified peptides exhibit bactericidal properties, effectively eliminating bacterial growth and preventing further spread of infections.
  • Broad Spectrum: The technology's peptides are effective against multiple APEC and Salmonella serotypes, offering a versatile and comprehensive solution to combat diverse strains.


Patent # Title Country
63/226,611 Novel Antimicrobial peptides effective against avian pathogenic Escherichia coli (APEC) and Salmonella United States of America

Loading icon